Moderna
Search results
Full U.S. prescribing information. Patient information. Learn more at www.kalydeco.com. View a list of Authorized Specialty Pharmacies and Distributors for TRIKAFTA ®, SYMDEKO ®, ORKAMBI ® and KALYDECO ® . View information about Vertex Connects for CASGEVY™, and the Vertex Guidance and Patient Support Program for TRIKAFTA ®, SYMDEKO ...
Dec 8, 2023 · BOSTON & ZUG, Switzerland -- (BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle c...
Mar 19, 2024 · 03-19-2024 MOST INNOVATIVE COMPANIES 2024. This company’s first-ever CRISPR-based drug is changing how we treat sickle cell disease. Vertex Pharmaceuticals’ Casgevy is the first gene-editing...
Jan 16, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years a...
Jan 30, 2024 · Vertex Pharmaceuticals of Boston announced Tuesday that it had developed an experimental drug that relieves moderate to severe pain, blocking pain signals before they can get to the brain. It...
Jul 22, 2022 · BOSTON -- (BUSINESS WIRE)--Jul. 22, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of the pivotal development program with the U.S. Food and Drug Administration (FDA), Vertex plans to advance the selective NaV1.8 in...
Nov 16, 2023 · BOSTON & ZUG, Switzerland -- (BUSINESS WIRE)--Nov. 16, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom ( U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [...
